Primary endpoints for randomised trials of cancer therapy

The Lancet

Volumn 371, Issue 9631, 2008, Pages 2156-2158

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 45849143717     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60933-2     Document Type: Note

References (12)

1. Hudis C., Barlow W., Costantino J., et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP System. J Clin Oncol 26 (2007) 2127-2132
2. The Arimidex, Tamoxifen, and Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
3. Coates A., Keshaviah A., Thürlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
4. Coombes R., Kilburn L., Snowdon C., et al., on behalf of the Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
5. Jakesz R., Jonat W., Gnant M., et al., on behalf of the ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
6. Goss P., Ingle J., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
7. Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99 (2007) 1845-1853
8. Hanrahan E., Gonzalez-Angulo A., Giordano S., et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25 (2007) 4952-4960
9. Punt C., Buyse M., Kohne C.-H., et al. Endpoints in adjuvant trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99 (2007) 998-1003
10. US Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. Clinical trial endpoints for the approval of cancer drugs and biologics (May, 2007). http://www.fda.gov/cder/guidance/7478fnl.htm (accessed May, 2007).
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
12. Gøtzsche P., and Olsen O. Is screening for breast cancer with mammography justifiable?. Lancet 355 (2000) 129-134